Biocon Biologics Drives Diabetes Care Progress in Ethiopia With Specialist Nurse Program

On November 27, 2024, Biocon Biologics, a subsidiary of Biocon Ltd, announced progress in its collaboration with Diabetes Africa and St. Paul’s Hospital in Ethiopia to train specialist nurses and improve diabetes care as part of a broader healthcare initiative.

Purpose and Impact

This initiative holds immense importance as Ethiopia reports a diabetes prevalence of 2–3%, placing it among the top four nations in sub-Saharan Africa with the highest adult diabetic population.

Diabetes accounts for nearly 2% of all deaths in the country, further underscoring the urgent need for action.

The shortage of skilled healthcare professionals, combined with the rising burden of diabetes, presents a critical health challenge.

Through this program, Biocon Biologics reaffirms its commitment to addressing these issues by strengthening healthcare systems and enhancing access to specialised diabetes care.

About St. Paul’s Hospital Millennium Medical College

St. Paul’s Hospital Millennium Medical College, located in Addis Ababa, Ethiopia, is a public tertiary care hospital and educational institution that provides medical services to more than 600,000 patients each year.

Biocon Share Price Performance

On November 28, 2024, Biocon share price was trading 0.98% higher at ₹362.15 at 9:40 AM on the NSE. The stock opened at ₹360 higher from its previous close of ₹358.65.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.